Mark J. Cameron, Ph.D.
Director of Genomics - Collaborative Genomics Center


Dr. Cameron is the Co-Director of the Collaborative Genomics Center (CGC) at VGTI Florida®. He has expertise in applying genomic technologies and a systems biology approach to defining gene expression correlates of pathogenesis and protection in human, non-human primate (NHP) and small mammal infectious disease and vaccination studies. He received his Ph.D. in Microbiology and Immunology in 2000 from the University of Western Ontario in London, Ontario, Canada.

At the University of Toronto, he gained 10 years of post-doctoral experience in leading collaborative genomic and bioinformatics teams by performing as Project Director in several Canadian Institutes of Health Research/Genome Canada genomics of infectious disease networks and NIH-issued federal business subcontracts. Since moving to VGTI Florida in 2010, he has been directing the scientific and operational activities of the Genomics and Bioinformatic groups comprising the CGC, as well as leading the functional genomics cores of several human clinical and animal model vaccine and immune correlate consortia funded by the NIH and Bill & Melinda Gates Foundation.

Dr. Cameron's main research interest is the role of interferon signaling genes and the inflammasome in regulating the innate and adaptive immune interface in response to human infectious disease and vaccination. By deciphering clinical, immunological and bioinformatic datasets, he has helped identify key innate immune response gene expression correlates that may provide a readout that is diagnostic and predictive of human protective immune responses. As someone who can translate bioinformatic results to biology, he has been involved in many functional genomics studies leading to the publication of over 55 papers in the field of vaccines and functional genomics of inflammatory, emerging and chronic infectious disease.